

Special Issue

Adverse Effects During Cancer Treatment

Message from the Guest Editor

Cancer has been one of the leading causes of death in the world. Due to the advancement of early detection and development of new and more effective cancer treatments in the last few decades, the mortality from cancer has been decreasing steadily. As such, adverse events during cancer treatment have been increasingly recognized as an important consideration in improving patients' long-term outcomes and quality of life. The adverse events during cancer treatment range from mild to severe or even life-threatening. This Special Issue will highlight various aspects of adverse events during cancer treatment, including, but not limited to, cardiotoxicity related to cancer medications or radiation therapy, immune-related adverse events during immunotherapy, and other relevant topics.

Guest Editor

Dr. Yan Gong

College of Pharmacy, University of Florida, Gainesville, FL 32611, USA

Deadline for manuscript submissions

30 April 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/260398

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)